This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Should You Buy Solaris Energy Infrastructure, Inc. (SEI) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SEIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
by Zacks Equity Research
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.
OMCLPositive Net Change ABTPositive Net Change GMEDNegative Net Change PAHCNegative Net Change
medical medical-devices
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings?
by Moumi Mondal
ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation below historical levels draw investor interest.
ABTPositive Net Change LHNegative Net Change TMONegative Net Change
earnings-preview medical medical-devices
3 Sales Growth Stocks to Buy as Q3 Earnings Get Underway
by Swayta Shah
Chipotle, BP and Intuitive Surgical stand out for strong sales growth, solid cash flow and favorable valuation metrics as Q3 earnings begin.
BPPositive Net Change CMGNegative Net Change ISRGPositive Net Change
medical medical-devices oil-energy restaurants retail
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
by Zacks Equity Research
AMN Healthcare's staffing demand, technology investments and growth prospects fuel optimism, but pricing pressure and segment weakness pose challenges.
AMNPositive Net Change MMSINegative Net Change OPKNo Net Change GMEDNegative Net Change
medical medical-devices
Dentsply Sirona Expands U.S. Digital Dentistry Reach With Midwest Deal
by Zacks Equity Research
XRAY expands its U.S. distribution reach through Midwest Dental, aiming to boost digital dentistry adoption and broaden access to its technology portfolio.
XRAYNegative Net Change MMSINegative Net Change OPKNo Net Change GMEDNegative Net Change
medical medical-devices
Take the Zacks Approach to Beat the Markets: HF Sinclair, Accenture & FirstCash in Focus
by Santanu Roy
HF Sinclair, Accenture and FirstCash post impressive gains as Zacks research portfolios highlight standout performers amid market uncertainty and shifting investor sentiment.
AMTPositive Net Change AMDPositive Net Change ACNNegative Net Change AVTNegative Net Change TSCONegative Net Change FCFSNegative Net Change HCAPositive Net Change MTDNegative Net Change TALNegative Net Change NOBLNegative Net Change LFSTPositive Net Change DINONegative Net Change
business-services computers consumer-discretionary medical medical-devices oil-energy reit retail
2 International Microcaps for Your Watchlist
by Mark Zinski
SSII and IVDA have sales predominantly in India and Taiwan, respectively.
IVDAPositive Net Change SSIINegative Net Change
artificial-intelligence medical-devices small-cap
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
by Zacks Equity Research
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
GKOSPositive Net Change MMSINegative Net Change OPKNo Net Change GMEDNegative Net Change
medical medical-devices
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
by Zacks Equity Research
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
ANGOPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTPositive Net Change
earnings medical medical-devices